[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100387550":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":47,"collaborators":20,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":20,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":20,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Oregon Health and Science University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"All subjects","EXPERIMENTAL","All subjects will have two PET\u002FCT scans on days 3 and 5 after SCS electrode implantation: (1) Baseline and (2) SCS-activated. Other than SCS activation, both studies will be conducted under identical conditions. For the first scan, subjects will be randomly assigned to either a baseline (no SCS during PET\u002FCT) or with SCS during PET\u002FCT prior to the day of their first scan. The second scan will complete the sequence with either a baseline or SCS-activated scan, as randomized.",[13],"Device: Research electrode",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Research electrode","A second electrode will be placed percutaneously by Tuohy needle in the epidural space at the same time as the SCS trial implant; at lateral T1-2 area randomly assigned to the left or right side of the lateral epidural space, at the time of the procedure. Placement of electrodes is not experimental, but the placement of a second electrode is a research-driven procedure.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Kim Burchiel, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","503-494-4314","burchiek@ohsu.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Oregon Health & Science University","RECRUITING","Portland","Oregon","97239","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-122.67621,45.52345,{"lat":43,"lon":42},[46],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Kim J. Burchiel","Professor","100387550","brown-adipose-tissue-activation-by-spinal-cord-stimulation-100387550",false,"NCT04326192","Brown Adipose Tissue Activation by Spinal Cord Stimulation","Inclusion Criteria:\n\n1. Age: 21-70 years\n2. Persistent neuropathic leg and back pain\n3. Subjects who are already planning to undergo SCS for pain\n4. Subjects who have not received a prior SCS trial for pain\n5. Subjects with a BMI of 25-45, using formula; weight (lb) \u002F \\[height (in)\\]2 x 703\n\nExclusion Criteria:\n\n1. Not considering SCS for pain\n2. Forensic patient\n3. Taking beta blockers\n4. Weight change \\> 5% within last 3 months\n5. Habitual tobacco use\n6. Habitual excessive alcohol use\n7. Pregnancy\n8. Decisionally impaired adults\n9. Children\n10. Neonates\n11. Subjects with a BMI of \\\u003C25 or \\>45","ALL","21 Years","70 Years",{"count":60,"type":61},10,"ESTIMATED","INTERVENTIONAL",[64],"NA","The objective of this study is to investigate and utilize spinal cord stimulation (SCS) as an effective approach to eliciting weight loss and potentially alleviating Type 2 diabetes mellitus (DM), as evidenced by increasing metabolism of adipose tissue.",[67,68,69],"Pain, Back","Obesity, Morbid","Type 2 Diabetes",[71,72],"Obesity","Diabetes","2024-04-01",{"date":75,"type":76},"2024-04-03","ACTUAL",{"date":78,"type":76},"2021-02-19",{"date":80,"type":61},"2026-10",{"name":5,"class":6},1]